Rare Disease Drug Partnership and Return of Rights with the GSK Group

Initiative to pursue regional co-development and commercialization of enzyme therapies for Fabry disease and Hunter syndrome through a capital and comprehensive partnership with the GSK Group, with amendments to the agreements resulting in the return of options in certain regions and all rights in other cases.